Cardiac magnetic resonance for tissue characterization based risk stratification of cardiopulmonary symptoms, effort tolerance, and prognosis among covid-19 survivors

Active Project Grant Awarded Last action

Award ID
R01HL159055
Recipient
Awarding agency
Obligated
$6,083,813

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 88% complete
Originally
Funding
  • $5,382,997.00 Federal
  • $700,816.00 Non-federal
Place of performance
New York, NY 10065, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic. Despite substantial short term mortality risk, the overwhelming majority of infected patients survive acute illness, resulting in a growing population at risk for long term events. Cardiopulmonary symptoms are common after COVID-19, as shown by survey data reporting fatigue (53%), dyspnea (43%), and worsened quality of life (44%) 60 days after acute infection, but mechanism and time course of symptoms are unknown. Recent studies and our own preliminary data have shown myocardial tissue abnormalities on cardiac magnetic resonance (CMR) to be common in COVID-19 survivors - raising the possibility that symptoms stem from viral effects on the heart. However, CMR findings to date are limited by small size and clinical data susceptible to referral bias, raising uncertainty as to generalizability. IT is also unknown whether altered myocardial tissue properties (fibrosis, edema) impact clinical outcomes. The central hypothesis of our research is that CMR tissue characterization will be incremental to clinical assessment and cardiac contractile function for prediction of long-term cardiopulmonary symptoms, effort tolerance, and prognosis among COVID-19 survivors. To test this, we will study patients from an active multi- ethnic NYC registry of COVID-19 survivors: we have already leveraged echocardiographic imaging data from this registry to show that (1) adverse cardiac remodeling (dilation, dysfunction) markedly augments short term mortality, (2) COVID-19 acutely alters left and right ventricular remodeling, and (3) many patients who survive initial hospitalization for COVID-19 have adverse cardiac remodeling - including 40% with left ventricular (LV) dysfunction and 32% with adverse RV remodeling (dilation, dysfunction): our current proposal will extend logically on our preliminary data to test whether CMR tissue characterization provides incremental predictive utility with respect to reverse remodeling and prognosis. At least 510 COVID-19 survivors will be studied. Echo will be analyzed at time of and following COVID-19 for longitudinal remodeling, as will CMR at pre-specified (6- 12, 36 month) follow-up timepoints. Established and novel CMR technologies will be employed, including assessment of cardiac and lung injury, high resolution (3D) myocardial tissue characterization, and cardiopulmonary blood oxygenation. In parallel, QOL, effort tolerance (6-minute walk test), biomarkers, and rigorous follow-up will be obtained to discern clinical implications and relative utility of imaging findings. Aim 1 will identify determinants of impaired quality of life and effort intolerance among COVID-19 survivors. Aim 2 will test whether myocardial tissue injury on CMR is associated with impaired contractility, and whether fibrosis predicts contractile recovery. Aim 3 will determine whether myocardial tissue injury is independently associated with adverse prognosis (new onset clinical heart failure, hospitalization, mortality). Results will address key knowledge gaps regarding COVID-19 effects on the heart necessary to guide surveillance, risk stratification, and targeted therapies for millions of COVID-19 survivors at risk for myocardial injury, cardiopulmonary symptoms, and adverse prognosis.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $701,089 $0
Amendment $0 $0
Amendment $625,046 $0
Amendment $640,107 $0
Amendment $640,107 $0
Amendment $687,508 $0
Amendment $687,508 $0
Amendment $700,816 $0
Original award $700,816 $700,816

Subawards

Subrecipient Amount Awarded
New York-Presbyterian / Queens The NYPQ study team will be directly responsible for the selection, enrollment of study subjects and supervision of data collection in compliance with the… $337,868
The New York And Presbyterian Hospital Drs. Kim and Weinsaft have jount faculty appointments at NYP-Queens Weill Cornell Medical College (NY Presbyterian Hospital) Jiwon Kim, MD (Principal… $151,396

Quick answers

Who received award R01HL159055?

R01HL159055 was awarded to Weill Medical College Of Cornell University by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2021.

How much is award R01HL159055 worth?

$6,083,813 has been obligated on R01HL159055: $5,382,997 in federal funding and $700,816 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login